{"componentChunkName":"component---src-templates-study-details-page-js","path":"/en/study/APV30005","result":{"data":{"studyNotFoundJson":{"title":"Study not found","content":{"childMarkdownRemark":{"html":"<p>If you entered a web address please check it was correct.</p>\n<p>You can also try <a href=\"/en/studies\">Search Page</a> to find the study you are looking for.</p>"}}},"trialDetailsJson":{"title":"Details Page","returnSearch":"Back to search results","description":"Study Description","identifier":"ViiV Study ID","clinicalID":"Clinicaltrials.gov Identifier","EudraCtID":"EudraCT Number","resultsAvailable":"Has Results Available Below","docAvailable":"Has Results Document Available","studyOverview":"Study Overview","overviewSection":{"conditionsDisplay":"Medical Conditions","product":"Product","collaborators":"Collaborators","dates":"Date","studyType":"Type","phase":"Phase","gender":"Gender","age":"Age","acceptVolunteers":"Accepts Healthy Volunteers"},"studyDocuments":"Study Documents","noDocuments":"No documents available","studyDocumentsAdditionalText":"If you wish to request for Full Study Report, please contact - ","studyDocumentsAdditionalEmail":"GSKClinicalSupportHD@gsk.com","isReleased":{"firstPart":"This study has Protocol and Result summary on ClinicalTrial.gov. Click","secondPart":"to learn more.","linkText":"here"},"mapLocations":"Locations","centralContact":"Central Contact","centralPhone":"Central Contact Phone","centralEmail":"Central Contact Email","mapSection":{"site":"GSK Investigational Site","condition":"Condition","id":"Study ID","city":"City","state":"State","zip":"Zip","country":"Country"},"studyDesign":"Study Design","designSection":{"purpose":"Primary Purpose","allocation":"Allocation","study_design":"Study Design","study_classification":"Study Classification","masking":"Masking","masked_subject":"Masked Subject","masked_caregiver":"Masked Caregiver","masked_investigator":"Masked Investigator","masked_assessor":"Masked Assessor","primary_outcomes":"Primary Outcomes","secondary_outcomes":"Secondary Outcomes","arms":"Arms","interventions":"Interventions","keyword":"Keyword","inclusionTitle":"Inclusion Criteria","exclusionTitle":"Exclusion Criteria","criteriaText":"Inclusion/Exclusion Criteria","criteria_button":"Click to view inclusion/exclusion criteria","enrollment":"Enrollment","clinicalPublications":"Clinical Publications"},"popoversText":{"studyId":{"childMarkdownRemark":{"html":"<p>A unique number for a study given by ViiV.</p>"}},"ctGov":{"childMarkdownRemark":{"html":"<p>This number identifies the study on the US clinicaltrials.gov register. Click this link to go to the entry for this study on Clinicaltrials.gov where you will be able to see protocol and results summaries where available.</p>"}},"eudraCT":{"childMarkdownRemark":{"html":"<p>This number identifies the study on the EU clinicaltrials.eu register. Click this link to go to the entry for this study on clinicaltrials.eu where you will be able to see protocol and results summaries where available.</p>"}}}},"site":{"siteMetadata":{"siteUrl":"https://www.viiv-studyregister.com"}},"studyDetails":{"nct_number":"NCT00296504","ctis_id":"","HasResults":"true","IpdAccessCriteria":"","IpdDescription":"","IpdInfoTypeAnalyticCode":"","IpdInfoTypeIcf":"","IpdInfoTypeCsr":"","IpdInfoTypeProtocol":"","IpdInfoTypeSap":"","IpdTimeFrame":"","IpdUrl":"","IsFlexibleTrial":false,"IsReleasedToCtGov":"true","MaskingInfo":{"masked_assessor":"false","masked_caregiver":"false","masked_investigator":"false","masked_subject":"false","masking_description":"","no_masking":""},"PatientLevelData":"false","SharingIpd":"","acronym":"","allocation":"Non-randomized","arm_groups":[],"assignment":"Single Group Assignment","brief_summary":"GW433908 (fosamprenavir; FPV)is a pro-drug of amprenavir (APV) which is more water soluble and can be formulated into a tablet with a reduced pill burden (four 700mg tablets of FPV versus sixteen 150mg capsules daily for APV. This study is designed to provide additional information on long term safety and tolerability of FPV containing regimens for those subjects who received FPV in previous GlaxoSmithKline studies.","brief_summary_OneLinkTx":"","brief_title_OneLinkTx":"","brief_title":"A Study To Assess GW433908 (Fosamprenavir) Containing Regimens In HIV-1 Infected Subjects","conditions":[{"DisplayValue":"Human Immunodeficiency Virus (HIV)","DisplayValue_OneLinkTx":"","InternalValue":"CON_HIV","LookupValue":"Infection, Human Immunodeficiency Virus","LookupValue_OneLinkTx":""}],"created_date":"09/15/2018 17:52:56","criteria":"Inclusion Criteria: - Male or non-pregnant/non-lactating females >/=13 years of age (or >/= 18 years of age according to local requirements). - Received fosamprenavir through prior participation in APV20001, APV30002, APV30003 or PRO30017 or have participated in APV30001 or other studies as deemed appropriate by the project team. Exclusion Criteria: - Permanent discontinuation of GW433908 in a previous study due to intolerance. - An active CDC Class C Event. - Any condition which, in the opinion of the investigator, would preclude a subject from participation.","detailed_description":"ViiV Healthcare is the new sponsor of this study, and GlaxoSmithKline is in the process of updating systems to reflect the change in sponsorship.","display_gender":"Both","display_gender_internal":"GENDER_ALL","display_phase":"Phase 3","display_phase_internal":"PHASE_3","display_status":"Completed","display_status_internal":"RECSTATUS_I_COMPLETED","endpoint":"","enrollment":"753","exclusion":"","gender":"Both","gender_based":"","gender_description":"","healthy_volunteers":"No","id":"94432418-dde5-52ff-a4ec-5bc307120ad6","internal":{"content":null,"contentDigest":"262f144097aac7318e490e51a8fe671b","description":null,"fieldOwners":null,"mediaType":null,"ignoreType":null,"owner":"default-site-plugin","type":"studyDetails"},"inclusion":"Inclusion Criteria: - Male or non-pregnant/non-lactating females >/=13 years of age (or >/= 18 years of age according to local requirements). - Received fosamprenavir through prior participation in APV20001, APV30002, APV30003 or PRO30017 or have participated in APV30001 or other studies as deemed appropriate by the project team. Exclusion Criteria: - Permanent discontinuation of GW433908 in a previous study due to intolerance. - An active CDC Class C Event. - Any condition which, in the opinion of the investigator, would preclude a subject from participation.","interventions":[{"arm_group_label":"","intervention_description":"","intervention_name":"fosamprenavir (GW433908)","intervention_type":"Drug"},{"arm_group_label":"","intervention_description":"","intervention_name":"ritonavir","intervention_type":"Drug"}],"interventional_subtype":"Treatment","is_fda_regulated":true,"is_high_value":false,"is_ind_study":true,"keywords":["antiretroviral therapy naive subjects","fosamprenavir","HIV-1","protease inhibitor","pro-drug","antiretroviral therapy","LEXIVA","AGENERASE","GW433908","amprenavir"],"last_follow_up_date":"10/01/2010 00:00:00","links":[],"locations":[{"City":"Sarasota","Latitude":"27.3086034","CountryDisplay":"United States","Longitude":"-82.5239953","Name":"GSK Investigational Site","StateDisplay":"Florida","PostalCode":"34239","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Fountain Valley","Latitude":"33.7168761","CountryDisplay":"United States","Longitude":"-117.9600466","Name":"GSK Investigational Site","StateDisplay":"California","PostalCode":"92708","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Paris Cedex 10","Latitude":"48.856614","CountryDisplay":"France","Longitude":"2.3522219","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"75475","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Manhasset","Latitude":"40.7960005","CountryDisplay":"United States","Longitude":"-73.6830521","Name":"GSK Investigational Site","StateDisplay":"New York","PostalCode":"11030","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Barcelona","Latitude":"41.3899238","CountryDisplay":"Spain","Longitude":"2.1511635","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"08036","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"London","Latitude":"51.4985226","CountryDisplay":"United Kingdom","Longitude":"-0.1195779","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"SE1 7EH","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Paris Cedex 20","Latitude":"48.8575475","CountryDisplay":"France","Longitude":"2.3513765","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"75970","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Genova","Latitude":"44.4013771","CountryDisplay":"Italy","Longitude":"8.9341937","Name":"GSK Investigational Site","StateDisplay":"Liguria","PostalCode":"16128","StatusDisplay":"Recruiting","StatusDisplayInternal":"LOCSTATUS_RECRUITING","StatusMapped":"Recruiting"},{"City":"Santiago","Latitude":"-33.4488897","CountryDisplay":"Chile","Longitude":"-70.6692655","Name":"GSK Investigational Site","StateDisplay":"Región Metro De Santiago","PostalCode":null,"StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Orlando","Latitude":"28.5085825","CountryDisplay":"United States","Longitude":"-81.3564411","Name":"GSK Investigational Site","StateDisplay":"Florida","PostalCode":"32806","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"San Francisco","Latitude":"37.7877522","CountryDisplay":"United States","Longitude":"-122.4382307","Name":"GSK Investigational Site","StateDisplay":"California","PostalCode":"94115-1931","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Marseille","Latitude":"43.2916612","CountryDisplay":"France","Longitude":"5.3965729","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"13005","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Coimbra","Latitude":"40.2191523","CountryDisplay":"Portugal","Longitude":"-8.4098211","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"3000-075","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Badajoz","Latitude":"38.8794495","CountryDisplay":"Spain","Longitude":"-6.9706535","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"6080","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Villejuif Cedex","Latitude":"48.7959755","CountryDisplay":"France","Longitude":"2.3494723","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"94805","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Orlando","Latitude":"28.5747416","CountryDisplay":"United States","Longitude":"-81.3949264","Name":"GSK Investigational Site","StateDisplay":"Florida","PostalCode":"32804","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"London","Latitude":"51.5531762","CountryDisplay":"United Kingdom","Longitude":"-0.1652792","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"NW3 2QG","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Fort Lauderdale","Latitude":"25.750008","CountryDisplay":"United States","Longitude":"-80.241826","Name":"GSK Investigational Site","StateDisplay":"Florida","PostalCode":"33145","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Le Kremlin Bicêtre Cedex","Latitude":"48.810108","CountryDisplay":"France","Longitude":"2.356972","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"94275","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Vandoeuvre Les Nancy Cedex","Latitude":"48.661118","CountryDisplay":"France","Longitude":"6.17376","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"54511","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Galveston","Latitude":"29.3013479","CountryDisplay":"United States","Longitude":"-94.7976958","Name":"GSK Investigational Site","StateDisplay":"Texas","PostalCode":"77555-1188","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Campinas","Latitude":"-22.9099384","CountryDisplay":"Brazil","Longitude":"-47.0626332","Name":"GSK Investigational Site","StateDisplay":"São Paulo","PostalCode":"13083970","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Denver","Latitude":"39.7167888","CountryDisplay":"United States","Longitude":"-104.9665815","Name":"GSK Investigational Site","StateDisplay":"Colorado","PostalCode":"80262","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Tampa","Latitude":"28.0133862","CountryDisplay":"United States","Longitude":"-82.5077593","Name":"GSK Investigational Site","StateDisplay":"Florida","PostalCode":"33614","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"}],"masking":"Open Label","maximum_age_raw":"N/A N/A","maximum_age":"N/A","minimum_age":"13","minimum_age_raw":"13 years","modified_date":"10/01/2018 23:00:06","number_of_arms":"","observational_design":{"biospecimen_description":"","biospecimen_retention":"","number_of_groups":"","observational_study_design":"","patient_registry":"","target_duration_quantity":"","target_duration_units":"","timing":""},"official_title":"An Open-Label Phase III Study to Assess the Long Term Safety Profile of GW433908 Containing Regimens in HIV-1 Infected Subjects","org_study_id":"APV30005","overall_contact":{"email":"GSKClinicalSupportHD@gsk.com","last_name":"Call Center","phone":"877-379-3718"},"overall_status":"Completed - Interventional","oversight_info":{"exported_from_us":"","fda_regulated_device":"","fda_regulated_drug":"","ped_postmarket_surv":"","has_dmc":false,"post_prior_to_approval":"","regulatory_authorities":[""]},"phase":"3","primary_compl_date":"10/01/2010 00:00:00","primary_outcomes":[],"product_name":"","product_name_OneLinkTx":"","secondary_ids":[],"secondary_outcomes":[{"outcome_description":null,"outcome_measure":null,"outcome_time_frame":null,"outcome_safety_issue":null}],"sponsors":{"investigator_affiliation":"","investigator_username":"","lead_sponsor":"ViiV Healthcare","collaborators":["GSK"]},"start_date":"11/01/2001 00:00:00","study_type":"Interventional","therapeutic_area":"Infectious Diseases","citations":[],"is_section_801":true}},"pageContext":{"studyId":"APV30005"}},"staticQueryHashes":["162689979","3332233851","3729204765","3769354840","399703114"]}